Exclusive Summary

• - Clear clinical value and guideline-preferred status for severe hospital infections (cUTI/cIAI/HAP/VAP) caused by KPC- and OXA-48-producing CRE and some MDR P. aeruginosa.
• - US/EU protected by key patents/SPCs into 2026–2030, while India and parts of Asia/MENA/LatAm are open, enabling selective go-to-market now and early positioning.
• - Versus US originator pricing >USD 1,000 per treatment day, generic markets like India achieve about USD 50–120/day, implying 40–80% systemwide price reductions.
• - Classified as Reserve on WHO AWaRe; recommended by IDSA/EU for KPC and OXA-48 CRE, and with aztreonam for MBL, providing clear differentiation.
• - Prioritize completing 36-month stability and expanding to ICH Zone IV to access SEA/Africa/Middle East tenders; absence of pharmacopeial monograph is manageable with validated in-house specs.